CL2014000819A1 - Compuestos heterociclicos derivados de etinilo, moduladores alostericos mglur5; proceso de preparacion; composicion farmaceutica; uso en la prevencion o el tratamiento de esquizofrenia, enfermedades cognitivas, sindrome de la x fragil o autismo. - Google Patents

Compuestos heterociclicos derivados de etinilo, moduladores alostericos mglur5; proceso de preparacion; composicion farmaceutica; uso en la prevencion o el tratamiento de esquizofrenia, enfermedades cognitivas, sindrome de la x fragil o autismo.

Info

Publication number
CL2014000819A1
CL2014000819A1 CL2014000819A CL2014000819A CL2014000819A1 CL 2014000819 A1 CL2014000819 A1 CL 2014000819A1 CL 2014000819 A CL2014000819 A CL 2014000819A CL 2014000819 A CL2014000819 A CL 2014000819A CL 2014000819 A1 CL2014000819 A1 CL 2014000819A1
Authority
CL
Chile
Prior art keywords
autism
schizophrenia
ethynyl
prevention
treatment
Prior art date
Application number
CL2014000819A
Other languages
English (en)
Inventor
Georg Jaeschke
Lothar Lindemann
Antonio Ricci
Daniel Rueher
Eric Vieira
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2014000819A1 publication Critical patent/CL2014000819A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014000819A 2011-10-07 2014-04-03 Compuestos heterociclicos derivados de etinilo, moduladores alostericos mglur5; proceso de preparacion; composicion farmaceutica; uso en la prevencion o el tratamiento de esquizofrenia, enfermedades cognitivas, sindrome de la x fragil o autismo. CL2014000819A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11184331 2011-10-07

Publications (1)

Publication Number Publication Date
CL2014000819A1 true CL2014000819A1 (es) 2014-09-22

Family

ID=46968237

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000819A CL2014000819A1 (es) 2011-10-07 2014-04-03 Compuestos heterociclicos derivados de etinilo, moduladores alostericos mglur5; proceso de preparacion; composicion farmaceutica; uso en la prevencion o el tratamiento de esquizofrenia, enfermedades cognitivas, sindrome de la x fragil o autismo.

Country Status (26)

Country Link
US (1) US8969338B2 (es)
EP (1) EP2763977B1 (es)
JP (1) JP5840793B2 (es)
KR (1) KR101637792B1 (es)
CN (1) CN103857668B (es)
AR (1) AR088246A1 (es)
AU (1) AU2012320598B2 (es)
BR (1) BR112014007898A2 (es)
CA (1) CA2850082C (es)
CL (1) CL2014000819A1 (es)
CO (1) CO6900143A2 (es)
CR (1) CR20140094A (es)
EA (1) EA024973B1 (es)
EC (1) ECSP14013296A (es)
ES (1) ES2564884T3 (es)
HK (1) HK1195298A1 (es)
IL (1) IL231783A (es)
IN (1) IN2014CN02478A (es)
MX (1) MX360667B (es)
MY (1) MY170822A (es)
PE (1) PE20141556A1 (es)
SG (1) SG11201401322UA (es)
TW (1) TWI468401B (es)
UA (1) UA110862C2 (es)
WO (1) WO2013050454A1 (es)
ZA (1) ZA201402069B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
UA113223C2 (xx) * 2012-08-13 2016-12-26 Арилетинілпіримідини
MY171517A (en) * 2012-10-18 2019-10-16 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
UA116023C2 (uk) * 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
MA38885B1 (fr) * 2013-09-25 2018-11-30 Hoffmann La Roche Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4)
PL3303316T3 (pl) 2015-06-03 2020-06-29 F. Hoffmann-La Roche Ag Pochodne etynylu
KR20180026438A (ko) 2015-07-15 2018-03-12 에프. 호프만-라 로슈 아게 대사형 글루타메이트 수용체 조절제로서의 에틴일 유도체
CN106632243B (zh) * 2015-10-28 2019-03-15 华领医药技术(上海)有限公司 吡咯烷衍生物
LT3484889T (lt) 2016-07-18 2020-11-10 F. Hoffmann-La Roche Ag Etinilo dariniai
CN111032659B (zh) * 2017-08-17 2022-09-09 豪夫迈·罗氏有限公司 用于治疗诸如帕金森病的疾病的咪唑并[1,2-a]咪唑-2-酮衍生物
CR20230314A (es) 2020-12-17 2023-08-18 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3213780B2 (ja) 1993-12-21 2001-10-02 キヤノン株式会社 光学活性化合物、これを含有する液晶組成物、該液晶組成物を用いた液晶素子並びにこれらを用いた表示方法、表示装置
JPH09151179A (ja) 1995-11-30 1997-06-10 Canon Inc 光学活性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた液晶装置及び表示方法
US6410728B1 (en) 2000-08-31 2002-06-25 Abbott Laboratories Oxazolidinone chemotherapeutic agents
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1809620B1 (en) 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
WO2008151184A1 (en) 2007-06-03 2008-12-11 Vanderbilt University Benzamide mglur5 positive allosteric modulators and methods of making and using same
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
US8772300B2 (en) * 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
KR101576343B1 (ko) * 2011-04-26 2015-12-09 에프. 호프만-라 로슈 아게 피라졸리딘-3-온 유도체
MY163164A (en) * 2011-04-26 2017-08-15 Hoffmann La Roche Ethynyl derivatives as positive allosteric modulators of the mglur5

Also Published As

Publication number Publication date
WO2013050454A1 (en) 2013-04-11
CN103857668A (zh) 2014-06-11
ZA201402069B (en) 2015-03-25
UA110862C2 (uk) 2016-02-25
US20130090332A1 (en) 2013-04-11
CN103857668B (zh) 2016-04-13
PE20141556A1 (es) 2014-10-30
EA024973B1 (ru) 2016-11-30
AR088246A1 (es) 2014-05-21
CO6900143A2 (es) 2014-03-20
US8969338B2 (en) 2015-03-03
MX2014004144A (es) 2014-07-28
HK1195298A1 (zh) 2014-11-07
IL231783A (en) 2015-09-24
AU2012320598B2 (en) 2016-10-13
EP2763977B1 (en) 2016-02-24
MY170822A (en) 2019-09-01
IL231783A0 (en) 2014-05-28
ECSP14013296A (es) 2014-05-31
BR112014007898A2 (pt) 2017-04-04
MX360667B (es) 2018-11-13
EP2763977A1 (en) 2014-08-13
TWI468401B (zh) 2015-01-11
KR101637792B1 (ko) 2016-07-07
KR20140077943A (ko) 2014-06-24
JP5840793B2 (ja) 2016-01-06
AU2012320598A1 (en) 2014-03-13
SG11201401322UA (en) 2014-09-26
CA2850082C (en) 2019-05-28
EA201490722A1 (ru) 2014-07-30
ES2564884T3 (es) 2016-03-29
JP2014528435A (ja) 2014-10-27
CR20140094A (es) 2014-05-15
TW201321365A (zh) 2013-06-01
CA2850082A1 (en) 2013-04-11
NZ621894A (en) 2016-03-31
IN2014CN02478A (es) 2015-06-19

Similar Documents

Publication Publication Date Title
CL2014000819A1 (es) Compuestos heterociclicos derivados de etinilo, moduladores alostericos mglur5; proceso de preparacion; composicion farmaceutica; uso en la prevencion o el tratamiento de esquizofrenia, enfermedades cognitivas, sindrome de la x fragil o autismo.
CL2012002771A1 (es) Compuestos derivados de ariletinilo sustituidos, moduladores de los receptores mglur5; proceso de obtencion; composicion farmaceutica; y su uso en el tratamiento o prevencion de la esquizofrenia, enfermedades cognitivas, sindrome de x fragil o el autismo.
CL2013001891A1 (es) Compuestos heterociclicos fusionados; composicion farmaceutica y uso en el tratamiento de la degeneracion macular asociada con la edad.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2013002125A1 (es) Compuestos derivados de imidazo[5,1-f][1,2,4]triazinas; composicion farmaceutica; y uso en el tratamiento del deterioro cognitivo asociado con esquizofrenia.
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
DK3632919T3 (da) Farmaceutiske sammensætninger omfattende imidazothiadiazol- og imidazopyrazinderivater som proteaseaktiverede receptor 4-(par4)- hæmmere til behandling af blodpladeaggregering
DK3251678T3 (da) Benzoxaborolderivater til behandling af bakterieinfektioner
CL2007002996A1 (es) Compuestos derivados de quinolina sustituido, moduladores de los receptores x del higado; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome coronario agudo, alzheimer, diabetes y aterosclerosis.
DOP2010000326A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CL2014001858A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
HK1196819A1 (zh) 雜環化合物、含有所述化合物的藥物及其用途和其製備方法
CO6880069A2 (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
CL2015001233A1 (es) Compuestos heteroaromáticos fusionados; composicion farmaceutica y el uso como ligandos d1 de dopamina en el tratamiento de enfermedades tales como esquizofrenia.
CL2013002971A1 (es) Compuestos derivados de 5-(fenil/piridinil-etinil)-2-piridina/2-pirimidina-carboxamida, moduladores mglur5; composición farmacéutica que los comprende; proceso de preparación de ellos; y su uso en el tratamiento de esquizofrenia o enfermedades cognitivas.
DK2773648T3 (da) Farmaceutiske forbindelser til anvendelse i behandlingen af clostridium difficile-infektion
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
CL2008000875A1 (es) Compuestos derivados de imidazolidin-2-ona; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como dislipidemia, diabetes, enfermedades inflamatorias, entre otras.
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
CL2014002048A1 (es) Compuestos derivados de 4-(benzoimidazol-2-il)-tiazol y derivados aza relacionados; composicion farmaceutica; y uso en la prevencion y el tratamiento de trastornos autoinmunes, inflamatorios, enfermedades infecciosas, entre otras.